Streamline PCI Workflow with Accurate Stent Placement
Ultreon™ 1.0 Software guides physicians through percutaneous coronary intervention (PCI) step-by-step following MLD MAX workflow and provides insights on morphology, vessel sizing, stent placement and post-stent optimization for more accurate decision-making.1
1 in 4 patients undergoing PCI, have moderate to severe calcium.3 If left undiagnosed and untreated, it adversely impacts PCI outcomes.4Calcified lesions limit stent expansion, which is a major predictor of stent failure, such as stent thrombosis and restenosis.5
Ultreon Software displays calcification on the morphology screen:
An orange arc around the cross-sectional view indicates the presence of calcium
Sizing: Automatic detection of vessel diameter via EEL or Lumen2
Ultreon™ 1.0 Software uses artificial intelligence (AI) to automatically detect external elastic lamina (EEL) and lumen to help identify landing zones for accurate stent placement.1,6
Length: Angiographic co-registration facilitates identification of accurate length
Diameter: External elastic lamina (EEL) and lumen help identify landing zones in healthy tissue for stent placement6
Lumen shown as a solid white or red contour line
EEL shown as the dotted white line in the cross-sectional image and lumen profile
Ultreon™ 1.0 Software sizing screen displays sizing for vessel length and diameter
Ultreon™ 1.0 Software sizing screen displays sizing for vessel length and diameter
Sizing screen displays a four panel view:2
Current selected frame
Proximal reference frame
Distal reference frame
Maximized lumen profile – user can maximize the lumen profile by clicking on the icon at top left corner of lumen profile view.
Once sizing assessment is complete, a user can move to the next step by clicking the Deployment tab.
Ultreon™ 1.0 Software displays a four-panel view sizing screen
Ultreon™ 1.0 Software displays a four-panel view sizing screen
Deployment: Facilitation of precise stent deployment2
Ultreon™ 1.0 Software facilitates accurate stent deployment through co-registered and live angio views side-by-side.
Users can select a full-screen co-registered view if desired
After stent deployment, a user can conduct an additional OCT pullback and access post-PCI optimization tools in the Review tab. Once that's complete, a user can move to the next step by clicking the Review tab for post-PCI optimization.
Ultreon™ 1.0 Software displays stent deployment screen with angio co-registration
Ultreon™ 1.0 Software displays stent deployment screen with angio co-registration
Post-PCI Guidance with Ultreon™ 1.0 Software
Review: Post-stent optimization2
Ultreon™ 1.0 Software displays instantaneous calculations of expansion and apposition values, reference lumen diameter and lumen diameter values in color-coded markers:
Ultreon™ 1.0 Software helps physicians to quickly detect stent malapposition on the cross-sectional and lumen profile views:
On the cross-sectional view, malapposed struts are indicated by yellow dots if the gap between the strut and the vessel wall exceeds the user’s preselected threshold setting.
On the Lumen profile, malapposed zones are indicated by yellow bands when there’s a cluster of malapposed struts of length ≥ 1 mm and maximum circumferential angle ≥ 90 degrees
Ultreon™ 1.0 Software displays Malapposition Indicator on the Review screen
Ultreon™ 1.0 Software displays Malapposition Indicator on the Review screen
Pullback Comparison2
Physicians can quickly compare any two pullbacks by clicking on the Menu icon in the upper right corner. See the result of your PCI through vessel visualization pre- and post-stenting on one screen.
Please Enter the Pop Up text to be displayed in Pop Up here.
References
Data on File at Abbott.
Ultreon™ 1.0 Software IFU. Refer to Instructions For Use (IFU) for additional information.
Dean Kereiakes, Disrupt CAD III: Lithotripsy for Vessel Preparation in Calcified Coronary Arteries Prior to Stenting, CLD. Dec 29, 2020.
Madhavan MV, Tarigopula M, Mintz GS, Maehara A, Stone GW, Généreux P. Coronary artery calcification: pathogenesis and prognostic implications. J Am Coll Cardiol. 2014 May 06;63(17):1703-14.
Shlofmitz, E., Sosa, F.A., Ali, Z.A., Waksman, R., Jeremias, A., & Shlofmitz, R. (2019). OCT-Guided Treatment of Calcified Coronary Artery Disease: Breaking the Barrier to Stent Expansion. Current Cardiovascular Imaging Reports, 12(8), 32.
Prati F, et al. Clinical impact of OCT findings during PCI: the CLI-OPCI II study. JACC: Cardiovasc Imaging. 2015;8(11):1297-1305. doi: 10.1016/j.jcmg.2015.08.013.
Indications
The Ultreon™ 1.0 Software is intended to be used only with compatible OPTIS™ Next Imaging Systems. The OPTIS™ Next Imaging System with a compatible Dragonfly™ OPTIS™ Imaging Catheter or Dragonfly OpStar™ Imaging Catheter is intended for the imaging of coronary arteries and is indicated in patients who are candidates for transluminal interventional procedures. The Dragonfly™ OPTIS™ Imaging Catheter or Dragonfly OpStar™ Imaging Catheter is intended for use in vessels 2.0 to 3.5 mm in diameter. The Dragonfly™ OPTIS™ Imaging Catheter or Dragonfly OpStar™ Imaging Catheter is not intended for use in the left main coronary artery or in a target vessel which has undergone a previous bypass procedure. The OPTIS™ Next Imaging System is intended for use in the catheterization and related cardiovascular specialty laboratories and will further compute and display various physiological parameters based on the output from one or more electrodes, transducers, or measuring devices. The physician may use the acquired physiological parameters, along with knowledge of patient history, medical expertise, and clinical judgment to determine if therapeutic intervention is indicated.
Contraindications: Use of the Ultreon™ 1.0 Software is contraindicated where introduction of any catheter would constitute a threat to patient safety.
Contraindications include:
Bacteremia or sepsis
Major coagulation system abnormalities
Patients diagnosed with coronary artery spasm
Patients disqualified for coronary artery bypass graft (CABG) surgery
Patients disqualified for percutaneous transluminal coronary angioplasty (PTCA)
Severe hemodynamic instability or shock
Total occlusion
Large thrombus
Acute renal failure
Inability to tolerate systemic anticoagulation is a contraindication to use of OCT for coronary imaging.
PressureWire™ Guidewire is contraindicated for use in the cerebral vasculature.
The system has no patient alarm functions. Do not use for cardiac monitoring.
Complications: The risks involved in vascular imaging include those associated with all catheterization procedures. The following complications may occur as a consequence of intravascular imaging and may necessitate additional medical treatment including surgical intervention.
Abnormal heart rhythm or arrhythmias
Acute myocardial infarction
Allergic reaction to the contrast media or drug administered for the procedure
Arterial dissection, injury, or perforation
Bleeding
Catheter access site reactions: sterile inflammation or granuloma
Coronary artery spasm
Death
Embolism
Myocardial ischemia
Renal insufficiency or failure from contrast media use
Repeat revascularization
Thrombus formation, abrupt closure, or total occlusion
Tissue necrosis
Unstable angina
Hypotension
Warnings:
Refer to the contrast media Instructions for Use for general warnings and precautions relating to use of contrast media.
The heart rate and mean pressure values shown on the OPTIS™ Next Imaging System are for reference only and are not intended to be used as the primary display.
The system may place the point of index value at the wrong location due to pressure artifacts, for example: abnormal heartbeats, artifacts in AO (Pa) caused by flushing of guiding catheter, or valve opening / closing. The physician should always confirm that the point selected by the system is a valid point for the calculation of index value.
Inside the catheterization laboratory, only port-powered USB drives may be connected to the USB port. Connecting externally powered devices to the USB port in the patient vicinity may compromise electrical isolation and cause patient injury.
To protect the privacy and security of sensitive information, including electronic protected health information (EPHI), and to protect the integrity of the system itself, the system should be located in a physically secure, access-controlled environment. Do not use the OPTIS™ Next Imaging System if there is reason to believe the system’s security has been compromised or if the system was unaccounted for during a period of time (i.e., misappropriated, modified, or tampered with).
Precautions:
Safety and effectiveness have been established for the following patient population: adult patients undergoing non-emergent percutaneous coronary interventions in lesions with reference vessel diameters between 2.0 to 3.5 mm, which were not located in the left main coronary artery or in a target vessel which has undergone previous bypass procedures.
Monitor the OCT image for indications of Dragonfly™ Imaging Catheter optical failure. If optical failure is suspected, remove the Dragonfly™ Imaging Catheter from the patient, press “Unload” on the drive motor and optical controller (DOC), detach the catheter, and replace it with a new one.
If the pullback triggers before contrast is injected, repeat the pullback.
For optimal imaging, only use 100% contrast media.
MAT-2104193 v3.0
DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?
CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.
Precautions
Please be sure to read it.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.
Are you a healthcare professional?
Test
yes
Precautions
Please be sure to read it.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.
Are you a healthcare professional?
Test
[prod, crx3, samplecontent, publish, crx3tar]
test
DO YOU WISH TO CONTINUE AND EXIT CARDIOVASCULAR.ABBOTT?
CONTENTS OF THE SITE ARE NOT UNDER THE CONTROL OF ABBOTT.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
Unless otherwise specified, all product and service names appearing in this Internet site are trademarks owned by or licensed to Abbott, its subsidiaries or affiliates. No use of any Abbott trademark, trade name, or trade dress in this site may be made without the prior written authorization of Abbott, except to identify the product or services of the company.
The following pages are intended for medical professionals and provide information on the proper use of products (medical devices, etc.) of Abbott Medical Japan GK.
The information provided here is not intended to provide information to patients and the general public.
OPTIS™ Next Imaging Systems and Software
